Publications by authors named "Abtan J"
Article Synopsis
- Patients without standard modifiable cardiovascular risk factors (SMuRFs) experience lower in-hospital mortality after a first heart attack compared to those with risk factors, but their long-term outcomes are less understood, especially in women.
- This study analyzed a large cohort of patients with stable coronary artery disease, comparing outcomes based on the presence or absence of SMuRFs over a 5-year period.
- Results showed that SMuRF-less patients had a significantly lower rate of cardiovascular death and non-fatal heart attacks, indicating that having fewer risk factors correlates with better long-term heart health outcomes.
Article Synopsis
- The study aimed to explore outcomes of transcatheter patent foramen ovale (PFO) closure in patients over 60 years old, particularly looking at recurrent cerebrovascular events (CVE) and atrial fibrillation (AF).
- Involving 689 patients, the procedural success rate was high at 99.4%, but there were notable risks: 9.6% of patients died during follow-up, and diabetes and atrial septal aneurysm were linked to increased CVE events.
- The findings suggest that while most older patients experience low rates of CVE and AF post-procedure, factors like diabetes, atrial septal aneurysms, and increasing age are important in guiding clinical decisions regarding PFO closure.
Article Synopsis
- Acute myocarditis is a serious heart condition caused by inflammation, and usual anti-inflammatory treatments didn't work in past studies.
- * Researchers are testing if a special treatment called anakinra, which targets a specific immune pathway, can help patients with this condition.
- * The ARAMIS trial is a study that involves 120 patients and aims to see if anakinra can reduce complications from myocarditis over 28 days after being discharged from the hospital.
Background: Conflicting data exist on the association between consumption of coffee or tea and cardiovascular outcomes, and few focus on patients with established coronary artery disease.
Aim: To describe the association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease, using an extensive contemporary international registry, allowing the identification of multiple potential confounders.
Methods: The Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) registry enrolled in 2009 and 2010 in 45 countries, with a 5-year follow-up.
Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure.
Eur Heart J Cardiovasc Pharmacother
November 2023
Aims: Temporary dual antiplatelet therapy (DAPT) is recommended following patent foramen ovale (PFO) percutaneous closure although its benefit, compared to single antiplatelet therapy (SAPT), has not been demonstrated in this setting. We aimed at assessing outcomes following PFO closure according to the antiplatelet strategy at discharge.
Methods And Results: The ambispective AIR-FORCE cohort included consecutive patients from seven centres in France and Canada undergoing PFO closure and discharged without anticoagulation.
Article Synopsis
- The THEMIS trial explores the efficacy of ticagrelor compared to a placebo in patients with diabetes and stable coronary artery disease (CAD), intending to evaluate participant eligibility based on existing criteria.
- Out of the 10,156 patients from the REACH registry with diabetes and stable CAD, 28.1% met the eligibility requirements for the study, while the majority were excluded mainly due to a history of myocardial infarction or the use of anticoagulants.
- The study highlights that while a significant number of patients are deemed eligible for THEMIS, many still have conditions that prevent their inclusion, indicating a need for careful selection in clinical trials.
Article Synopsis
- This study examines the prevalence and impact of procedural complications during percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndrome (NSTE ACS).
- Out of 8,656 patients analyzed, 5.2% experienced complications, with the most common being no/slow reflow and dissection affecting blood flow.
- Complications significantly increased the risk of adverse outcomes, including death and myocardial infarction, while pre-procedure clinical characteristics were generally not predictive of complications.
Background: Transcatheter mitral valve implantation (TMVI) is emerging as an alternative to surgical mitral valve replacement in selected high-risk patients. Delaying definitive mechanical mitral valve replacement and the constraints of anticoagulation thanks to TMVI may be an attractive option in young women contemplating pregnancy and suffering from failure of mitral bioprosthesis or annuloplasty. The aim of the study was to evaluate the possibility, safety, and outcomes of pregnancy after TMVI in this population.
View Article and Find Full Text PDFBackground: Previous studies published before the era of systematic early invasive strategy have reported a higher mortality in non-ST-segment elevation myocardial infarction patients with heart failure. The aim of our study was to compare the clinical characteristics, outcomes and causes of death of patients according to their heart failure status at admission in a large non-ST-segment elevation myocardial infarction population with planned early invasive management.
Methods: We performed a post-hoc analysis of the Treatment of Acute Coronary Syndrome with Otamixaban randomised trial which included non-ST-segment elevation myocardial infarction patients with systematic coronary angiography within 72 h.
Background: Coronary angiography (CA) is usually performed in patients with reduced left ventricular ejection fraction (LVEF) to search ischemic cardiomyopathy. Our aim was to examine the agreement between CA and cardiovascular magnetic resonance (CMR) imaging among a cohort of patients with unexplained reduced LVEF, and estimate what would have been the consequences of using CMR imaging as the first-line examination.
Methods: Three hundred five patients with unexplained reduced LVEF of ≤45% who underwent both CA and CMR imaging were retrospectively registered.
Background: Following the publication of the COMPASS trial, the European Medicines Agency has approved a regimen of combination of rivaroxaban 2.5mg twice daily and a daily dose of 75-100mg acetylsalicylic acid (ASA) for patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischemic events. However, the applicability of such a therapeutic strategy in France is currently unknown.
View Article and Find Full Text PDFThe aim of this study was to describe the effects of chronic systemic corticosteroid treatment (SCT) on early and late outcomes after transcatheter aortic valve implantation (TAVI). From October 2006 to November 2018, 1,299 patients underwent TAVI in our institution. Among them, 48 (3.
View Article and Find Full Text PDFBackground: The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and ischemic stroke of atherosclerotic origin. The target level for low-density lipoprotein (LDL) cholesterol to reduce cardiovascular events after stroke has not been well studied.
Methods: In this parallel-group trial conducted in France and South Korea, we randomly assigned patients with ischemic stroke in the previous 3 months or a TIA within the previous 15 days to a target LDL cholesterol level of less than 70 mg per deciliter (1.
Background: We report the implementation of a large-scale simulation-based cardiovascular diagnostics course for undergraduate medical students.
Methods: A simulation-based course was integrated into the curriculum of second-year medical students (> 400 students/year). The first session aimed at teaching cardiac auscultation skills on mannequins and the second at teaching blood pressure measurement, peripheral arterial examination, and the clinical examination of heart failure in a technical skill-based manner and in a scenario.
Background: Despite the worldwide development of transcatheter aortic valve implantation (TAVI) over the last decade, strategies that take patient characteristics into account to guide the choice of transcatheter heart valve have not been evaluated.
Aim: To evaluate the immediate results of TAVI using a tailored choice of balloon-expandable or self-expanding transcatheter heart valve, according to each patient's clinical and anatomical characteristics.
Methods: This single-centre observational study included all patients treated with TAVI from 2012 to 2017.
Background: The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial found clinical benefit of low-dose rivaroxaban plus aspirin, but at the expense of increased bleeding risk in patients with stable vascular disease.
Objectives: This study evaluated the balance of ischemic and bleeding risks according to the presence of ≥1 enrichment criteria in "COMPASS-eligible" patients.
Methods: Key COMPASS selection criteria were applied to identify a COMPASS-eligible population (n = 16,875) from the REACH (REduction of Atherothrombosis for Continued Health) Registry of stable atherothrombotic patients.
Background: In patients undergoing percutaneous coronary intervention (PCI), who did not receive P2Y inhibitor pretreatment, the optimal timing of P2Y inhibitor loading dose remains debated. We sought to examine whether the choice of administration of the clopidogrel loading dose before or after the start of PCI had an impact on periprocedural complications, including bleeding.
Methods And Results: The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) double-blind randomized trial compared cangrelor with clopidogrel loading dose at the time of PCI.
Background: The aim of this study was to compare the diagnostic performances for the detection of myocardial ischemia of 82-Rb-PET-MPS and 99m-Tc-SPECT-MPS in overweight individuals and women.
Methods And Results: Men with BMI ≥ 25 and women referred for MPS were considered for inclusion. All individuals underwent 99m-Tc-SPECT-MPS with CZT cameras and 82-Rb-PET-MPS in 3D-mode.
Aims: To describe the characteristics and outcomes of patients receiving bailout glycoprotein IIb/IIIa inhibitors (GPI) for thrombotic complications of percutaneous coronary intervention (PCI) in a large, contemporary trial.
Methods And Results: In the CHAMPION PHOENIX trial, the use of GPI was restricted to bailout for thrombotic complications. We describe the characteristics and outcomes of patients requiring bailout GPI compared to patients not receiving GPIs, with adjustment through propensity-score.